A double-blind, randomised, placebo-controlled study to determine the safety, pharmacokinetics and maximum tolerated dose of NRP2945 in healthy adult volunteers.
Phase 1
Recruiting
- Conditions
- Severe childhood epilepsy (Lennox-Gastaut Syndrome)
- Registration Number
- ACTRN12617000377336
- Lead Sponsor
- CuroNZ Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 49
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method